Janux Therapeutics, Inc. Interest and Other Income
Janux Therapeutics, Inc. (JANX) reported Interest and Other Income of $9.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-06
- Janux Therapeutics, Inc. interest and other income for the quarter ending 2026-06-30 was $9.72M, a 13.69% decline year-over-year.
- Janux Therapeutics, Inc. interest and other income for the quarter ending 2026-03-31 was $9.85M, a 13.50% decline year-over-year.
- Janux Therapeutics, Inc. interest and other income for the quarter ending 2025-12-31 was $10.46M, a 18.73% increase year-over-year.
- Janux Therapeutics, Inc. interest and other income for the quarter ending 2025-09-30 was $10.94M, a 40.54% increase year-over-year.
- Janux Therapeutics, Inc. interest and other income for fiscal 2025 was $44.04M, a 47.53% increase from fiscal 2024.
- Janux Therapeutics, Inc. interest and other income for fiscal 2024 was $29.85M, a 103.28% increase from fiscal 2023.
- Janux Therapeutics, Inc. interest and other income for fiscal 2023 was $14.69M, a 264.24% increase from fiscal 2022.
- Janux Therapeutics, Inc. interest and other income for fiscal 2022 was $4.03M, a 1468.87% increase from fiscal 2021.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.72M 10-Q · filed 2026-08-06 | $19.57M 10-Q · filed 2026-08-06 | $30.02M derived: sum of 3 quarters · filed 2026-08-06 | $40.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.85M 10-Q · filed 2026-05-07 | $20.31M derived: sum of 2 quarters · filed 2026-05-07 | $31.25M derived: sum of 3 quarters · filed 2026-05-07 | $42.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.39M derived: sum of 2 quarters · filed 2026-02-26 | $32.65M derived: sum of 3 quarters · filed 2026-08-06 | $44.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | $10.94M 10-Q · filed 2025-11-06 | $22.20M derived: sum of 2 quarters · filed 2026-08-06 | $33.59M 10-Q · filed 2025-11-06 | $42.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.26M 10-Q · filed 2026-08-06 | $22.65M 10-Q · filed 2026-08-06 | $31.45M derived: sum of 3 quarters · filed 2026-08-06 | $39.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.39M 10-Q · filed 2026-05-07 | $20.20M derived: sum of 2 quarters · filed 2026-05-07 | $27.98M derived: sum of 3 quarters · filed 2026-05-07 | $35.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.59M derived: sum of 2 quarters · filed 2026-02-26 | $24.45M derived: sum of 3 quarters · filed 2026-02-26 | $29.85M 10-K · filed 2026-02-26 |
| 2024-09-30 | $7.78M 10-Q · filed 2025-11-06 | $15.65M derived: sum of 2 quarters · filed 2025-11-06 | $21.05M 10-Q · filed 2025-11-06 | $25.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $7.86M 10-Q · filed 2025-08-07 | $13.26M 10-Q · filed 2025-08-07 | $17.64M derived: sum of 3 quarters · filed 2026-02-26 | $21.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.40M 10-Q · filed 2025-05-08 | $9.78M derived: sum of 2 quarters · filed 2026-02-26 | $14.03M derived: sum of 3 quarters · filed 2026-02-26 | $17.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.62M derived: sum of 2 quarters · filed 2026-02-26 | $11.86M derived: sum of 3 quarters · filed 2026-02-26 | $14.69M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.25M 10-Q · filed 2024-11-06 | $7.49M derived: sum of 2 quarters · filed 2024-11-06 | $10.31M 10-Q · filed 2024-11-06 | $12.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.24M 10-Q · filed 2024-08-07 | $6.06M 10-Q · filed 2024-08-07 | $8.26M derived: sum of 3 quarters · filed 2025-02-27 | $9.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.82M 10-Q · filed 2024-05-08 | $5.02M derived: sum of 2 quarters · filed 2025-02-27 | $6.35M derived: sum of 3 quarters · filed 2025-02-27 | $6.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.53M derived: sum of 2 quarters · filed 2025-02-27 | $3.90M derived: sum of 3 quarters · filed 2025-02-27 | $4.03M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.33M 10-Q · filed 2023-11-07 | $1.70M derived: sum of 2 quarters · filed 2023-11-07 | $1.83M 10-Q · filed 2023-11-07 | $1.91M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $373.00K 10-Q · filed 2023-08-08 | $505.00K 10-Q · filed 2023-08-08 | $579.00K derived: sum of 3 quarters · filed 2023-08-08 | $716.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $132.00K 10-Q · filed 2023-05-09 | $206.00K derived: sum of 2 quarters · filed 2023-05-09 | $343.00K derived: sum of 3 quarters · filed 2023-05-09 | $389.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $211.00K derived: sum of 2 quarters · filed 2023-03-10 | $257.00K derived: sum of 3 quarters · filed 2023-03-10 | $257.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $137.00K 10-Q · filed 2022-11-10 | $183.00K derived: sum of 2 quarters · filed 2022-11-10 | $183.00K 10-Q · filed 2022-11-10 | $183.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $46.00K 10-Q · filed 2022-08-09 | $46.00K 10-Q · filed 2022-08-09 | $46.00K derived: sum of 3 quarters · filed 2022-08-09 | $46.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | $0.00 derived: sum of 3 quarters · filed 2022-05-10 | $0.00 derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 derived: sum of 3 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |